Is Cellectis S.A. (CLLS) a buy?

CLLS currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.

What is Cellectis S.A.'s quality score?

CLLS scores 37.433720601141545/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

CLLSCellectis S.A.

Next earnings Aug 3, 2026 · consensus $-0.28 EPS, $13.6M rev

Sell

$2.99

▼ -5.77%

SellMixed signals in the latest filings.Full call ↓

$2.99▲ +86.88%

over 1Y

L $1.59H $5.35

Today

-5.8%

-9.1%

-6.0%

-16.7%

YTD

-37.7%

+86.9%

Sell

Conviction

Horizon

Medium (3–12mo)

Street · 13 analysts

Buy

Mixed signals in the latest filings.

This call stands until the filings change it — the engine re-rates on new 10-K/10-Q/8-K facts, never on price moves. Hit Watch above to follow CLLS (Pro alerts fire the moment a rating flips), or catch every change in Saturday’s Flip Side. How to read a call

Cellectis S.A. shows limited reported revenue.

On these fundamentals, CLLS screens as SELL on the SEC figures.

Is CLLS a buy? The one-page verdict, explained →

The options angle

model · matches our verdict

Bear put spread~60d expiry

Long put 3 @ ~0.31 est
Short put 2.5 @ ~0.10 est

debit $21max +$29max −$21BE 2.79

SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.

Open in the calculator →

Browse all model plays →

Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.

Financialsannual, by fiscal year

No income data filed.

10-year statements — income, cash flow, balance sheet & CSV export →

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$320M

EV / EBITDA—

EV / Sales—

EV / FCF—

P / FCF—

PEG (trailing)—

Earnings yield—

FCF yield—

Quality & risk

ROIC (est.)—

Free cash flow—

Total debt—

Net cash—

Capital returns

Buyback yield—

Dividend yield (est.)—

Shareholder yield—

Shares Δ YoY+57.1%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗

Frequently asked

Is Cellectis S.A. (CLLS) a buy?: CLLS currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
What is Cellectis S.A.'s quality score?: CLLS scores 37.433720601141545/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001627281, latest 6-K/A filed 2026-06-26) · EODHD · as of 7/11/2026, 10:42:11 AM.

About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice

Rule-based analysis, generated automatically from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 11, 2026, 6:42 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

CLLSCellectis S.A.

Next earnings Aug 3, 2026 · consensus $-0.28 EPS, $13.6M rev

Sell

$2.99

▼ -5.77%

SellMixed signals in the latest filings.Full call ↓

$2.99▲ +86.88%

over 1Y

L $1.59H $5.35

Today

-5.8%

-9.1%

-6.0%

-16.7%

YTD

-37.7%

+86.9%

Sell

Conviction

Horizon

Medium (3–12mo)

Street · 13 analysts

Buy

Mixed signals in the latest filings.

Cellectis S.A. shows limited reported revenue.

On these fundamentals, CLLS screens as SELL on the SEC figures.

Is CLLS a buy? The one-page verdict, explained →

The options angle

model · matches our verdict

Bear put spread~60d expiry

Long put 3 @ ~0.31 est
Short put 2.5 @ ~0.10 est

debit $21max +$29max −$21BE 2.79

SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.

Open in the calculator →

Browse all model plays →

Financialsannual, by fiscal year

No income data filed.

10-year statements — income, cash flow, balance sheet & CSV export →

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$320M

EV / EBITDA—

EV / Sales—

EV / FCF—

P / FCF—

PEG (trailing)—

Earnings yield—

FCF yield—

Quality & risk

ROIC (est.)—

Free cash flow—

Total debt—

Net cash—

Capital returns

Buyback yield—

Dividend yield (est.)—

Shareholder yield—

Shares Δ YoY+57.1%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Insider activityForm 4 · SEC

all insiders →

2020-10-16	Cellectis S.A. 10% owner	Acquired (J)	1.25M @ $4.00	$5.00M
2018-06-15	Cellectis S.A. 10% owner	Buy	63.2K @ $19.49	$1.23M
2018-05-17	Cellectis S.A. 10% owner	Acquired (J)	550K @ $15.00	$8.25M

ETF ownershipForm N-PORT · SEC · quarterly

IBBiShares Biotechnology ETF

0.01%

$1.08M

Weight = the ETF’s percent of assets in CLLS, as of each fund’s latest public N-PORT (period end 2026-03-31) — a delayed, roughly quarterly snapshot filed ~2 months after the period, not a live position.

Ownership stakes

SEC · 13D / 13G

2025-12-12Activist 13D11.1%AmendedBpifrance Participations SAFiling ↗

Schedule 13D/13G filings disclosing a >5% stake in the company. A 13D declares intent to engage — read the filing; a 13G is a passive holding. Percent is the percent-of-class stated on the cover page. Source: SEC EDGAR (public domain).

Fails-to-deliver

SEC · settled 2026-06-10

130.00shares failed to deliver0.1× median

CLLS fails-to-deliver history — every published settlement day →

Aggregate CNS settlement fails on the latest published day, vs this name’s trailing median. From SEC fails-to-deliver data (published twice monthly) — a settlement metric, not short interest.

SEC correspondence

SEC · UPLOAD / CORRESP

2025-07-09Company responseCORRESPFiling ↗

2025-07-07SEC letterUPLOADFiling ↗

2025-01-21Company responseCORRESPFiling ↗

2025-01-16SEC letterUPLOADFiling ↗

CLLS SEC comment-letter history — every letter and response →

SEC staff comment letters (UPLOAD) questioning the company’s disclosures and its written responses (CORRESP), from the SEC’s filing review. Reviews are routine and this is not an assertion of wrongdoing; correspondence is released about 20 business days after a review concludes, so dates reflect the letter itself, not its release. Source: SEC EDGAR (public domain).

Recent news

market news →

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?Bullish

nasdaq.com· 2026-07-04

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?Bullish

finance.yahoo.com· 2026-07-04

Ferretti Leads The Charge In European Penny Stock OpportunitiesBullish

finance.yahoo.com· 2026-06-12

Cellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026Bullish

globenewswire.com· 2026-06-11

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 CongressBullish

globenewswire.com· 2026-06-11

Biggest stock movers Wednesday: CBRL, CLLS, SMCI, trucking stocks, and moreBullish

seekingalpha.com· 2026-06-10

Recent filings

all on EDGAR ↗

Frequently asked

Is Cellectis S.A. (CLLS) a buy?: CLLS currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
What is Cellectis S.A.'s quality score?: CLLS scores 37.433720601141545/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001627281, latest 6-K/A filed 2026-06-26) · EODHD · as of 7/11/2026, 10:42:11 AM.

About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice

Rule-based analysis, generated automatically from SEC filing data.

CLLSCellectis S.A.

The options angle

Financialsannual, by fiscal year

Key statistics

Valuation

Quality & risk

Capital returns

Recent filings

Frequently asked

CLLSCellectis S.A.

The options angle

Financialsannual, by fiscal year

Key statistics

Valuation

Quality & risk

Capital returns

Insider activityForm 4 · SEC

ETF ownershipForm N-PORT · SEC · quarterly

Ownership stakes

Fails-to-deliver

SEC correspondence

Recent news

Recent filings

Frequently asked

Insider activityForm 4 · SEC

ETF ownershipForm N-PORT · SEC · quarterly

Ownership stakes

Fails-to-deliver

SEC correspondence

Recent news

Vs tracked universe

News sentiment